Roivant Sciences (ROIV) Reiterated at Overweight by JPMorgan on Lisraya Feedback
Tweet Send to a Friend
JPMorgan analyst Brian Cheng reiterated an Overweight rating on Roivant Sciences (NASDAQ: ROIV).The analyst commented, "We recently conducted a doctor ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




